Bleeding Disorders Treatment Market Growth & Forecast [2031]
Bleeding Disorders Treatment Market Growth & Forecast [2031]
Segments - Global Bleeding Disorders Treatment Market by Types (Hemophilia A, Hemophilia B, Von Wilebrands Disease, and Others), Drug Classes (Plasma-derived Coagulation Factor Concentrates [Factor VIII, Factor IX, Factor for Von Willebrand Disease, and Activated Prothrombin Complex Concentrate], Recombinant Coagulation Factor Concentrates [Factor VIII, Factor for Von Willebrand Disease, and Factor IX], Desmopressin, Antifibrinolytics, and Fibrin Sealants), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Forecasts, 2021-2028
Upcoming
| Report ID :HC-4493
| 4.5 Rating
| 67 Reviews
| 175 Pages
| Format :
Report Description
The global bleeding disorders treatment market is expected to reach USD 20.42 billion by 2025, expanding at a CAGR of 7.65% during the forecast period. Bleeding disorder or simply known as hemophilia can be described as a condition that disturbs the regular process of blood coagulation, which results to the failure of blood clots. In general, these bleeding problems are majorly inherited although others are caused by liver illness or other factors. The growth of the global bleeding disorders treatment market is due to the rising number of people suffering from liver disease, anemia, and other blood coagulation disorders.
Market Trends, Drivers, Restraints, and Opportunities:
- Growing need for better quality healthcare facilities in developing countries to meet the needs of a growing urban population. This is expected to boost the market growth during the forecast period.
- Increasing awareness of the disorder among public along with massive R&D activity by major pharmaceutical companies for the development of novel medications for treating hemophilia are key drivers of the market.
- Scarcity of competent individuals and trained experts in handling testing devices is a major challenge projected to hamper the market expansion in the coming years.
- High medicine prices and lack of acceptable reimbursement policies are anticipated to further limit the scope of market growth during the projected period.
- Availability of low-cost generic pharmaceutical products in various developing nations and establishment of a large network of diagnosis and treatment centers across the globe are projected to offer lucrative opportunities in the market.
Scope of the report:
The report on the global bleeding disorders treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Report Title |
Bleeding Disorders Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018 & 2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Hemophilia A, Hemophilia B, Von Wilebrands Disease, and Others), Drug Classes (Plasma-derived Coagulation Factor Concentrates [Factor VIII, Factor IX, Factor for Von Willebrand Disease, and Activated Prothrombin Complex Concentrate], Recombinant Coagulation Factor Concentrates [Factor VIII, Factor for Von Willebrand Disease, and Factor IX], Desmopressin, Antifibrinolytics, and Fibrin Sealants), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
|
Regional Scope |
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
|
Report Coverage |
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast |
|
Key Players Covered |
Novo Nordisk; Bayer AG; Baxter International Inc.; Alnylam Pharmaceuticals, Inc.; Pfizer, Inc.; Xenetic Biosciences, Inc.; Bristol-Myers Squibb Company; Sanofi; Amgen, Inc.; Janssen Global Services; and others |
Bleeding Disorders Treatment Market Segment Insights
Hemophilia A segment is expected to grow at a fast rate
On the basis of types, the global bleeding disorders treatment market is segmented into hemophilia A, hemophilia B, Von Willebrand disease, and others. The hemophilia A segment is expected to grow at a fast rate during the forecast period owing to the increase in R&D spending for hemophilia products. Moreover, the wide prevalence of the disorder type worldwide especially in developing countries presents another key factor, which is projected to drive the segment growth in the coming years.
Recombinant coagulation factor concentrates segment is projected to exhibit a high growth rate
Based on drug classes, the market is divided into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, and fibrin sealants. The plasma-derived coagulation factor concentrates segment is further classified as factor VIII, factor IX, factor for Von Willebrand disease, and activated prothrombin complex concentrate. Moreover, the recombinant coagulation factor concentrates segment is sub-divided into Factor VIII, factor for Von Willebrand disease, and factor IX. The recombinant coagulation factor concentrates segment is projected to exhibit a high growth rate in the coming year due to increased R&D activity and rising pharmaceutical companies' focus on recombinant goods, which results in the release of new medications.
Hospitals pharmacies segment is anticipated to grow significantly
On the basis of distribution channels, the global bleeding disorders treatment market is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to grow significantly during the forecast period due to an increase in the number of diagnostic laboratories and availability of treatment centers in hospitals.
North America is expected to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to maintain its dominance in the market during the forecast period owing to the high incidence of prophylactic therapy uptake in the United States and Canada. However, the market of Asia Pacific is projected to hold a key market share in the coming years due to the enormous patient pool and increased expenditure to upgrade healthcare infrastructure in the region. The market of Europe, on the other hand, is anticipated to account for a large market share owing to rising research costs, technological advancements, declining human health, and the need for novel and effective cures.
Segments
By Types- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
- Novo Nordisk
- Bayer AG
- Baxter International Inc.
- Alnylam Pharmaceuticals, Inc.
- Pfizer, Inc.
- Xenetic Biosciences, Inc.
- Bristol-Myers Squibb Company
- Sanofi
- Amgen, Inc.
- Janssen Global Services
- Others
Competitive Landscape
Key players in the global bleeding disorders treatment market are Novo Nordisk; Bayer AG; Baxter International Inc.; Alnylam Pharmaceuticals, Inc.; Pfizer, Inc.; Xenetic Biosciences, Inc.; Bristol-Myers Squibb Company; Sanofi; Amgen, Inc.; Janssen Global Services; and others. These players engage in unions & attainments, collaborations, contracts, and partnerships to strengthen their geographical reach along with launching new products and massive investment in R&D activities.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Bleeding Disorders Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Bleeding Disorders Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Bleeding Disorders Treatment Market - Supply Chain
4.5. Global Bleeding Disorders Treatment Market Forecast
4.5.1. Bleeding Disorders Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Bleeding Disorders Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Bleeding Disorders Treatment Market Absolute $ Opportunity
5. Global Bleeding Disorders Treatment Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Bleeding Disorders Treatment Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
6. North America Bleeding Disorders Treatment Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Bleeding Disorders Treatment Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
7. Latin America Bleeding Disorders Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Bleeding Disorders Treatment Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
8. Europe Bleeding Disorders Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Bleeding Disorders Treatment Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Bleeding Disorders Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Bleeding Disorders Treatment Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Bleeding Disorders Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Bleeding Disorders Treatment Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Bleeding Disorders Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Bleeding Disorders Treatment Market: Market Share Analysis
11.2. Bleeding Disorders Treatment Distributors and Customers
11.3. Bleeding Disorders Treatment Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Novo Nordisk
11.4.2. Bayer AG
11.4.3. Baxter International Inc.
11.4.4. Alnylam Pharmaceuticals, Inc.
11.4.5. Pfizer, Inc.
11.4.6. Xenetic Biosciences, Inc.
11.4.7. Bristol-Myers Squibb Company
Methodology
Related Reports
Some other reports from this category!
Our Clients
